STOCK TITAN

Amgen Inc - AMGN STOCK NEWS

Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.

Amgen Inc. (AMGN) is a global biotechnology leader pioneering innovative therapies for serious illnesses. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's latest developments, regulatory milestones, and strategic initiatives.

Track critical updates across Amgen's core therapeutic areas including oncology treatments, inflammatory disease therapies, and rare disease solutions. Our curated feed includes earnings reports, clinical trial data, partnership announcements, and manufacturing updates - all sourced directly from official channels.

Key resources include timely coverage of FDA decisions, research breakthroughs in biologics and biosimilars, and analysis of market-moving events. Bookmark this page for structured access to Amgen's evolving pipeline and business strategies without promotional bias.

Rhea-AI Summary

Amgen (NASDAQ:AMGN) will present at Citi's 16th Annual BioPharma Conference on Sept. 8, 2021, at 1:25 p.m. ET. Murdo Gordon, Amgen's executive vice president of Global Commercial Operations, will lead the presentation. The event will be available for live audio streaming for media, investors, and the public via Amgen's website, where it will also be archived for 90 days post-event. Amgen, a biotechnology leader since 1980, focuses on developing innovative therapeutics for serious medical conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
conferences
-
Rhea-AI Summary

Amgen reported Q2 2021 revenues of $6.5 billion, a 5% increase year-over-year, driven by strong unit demand despite lower net selling prices. GAAP EPS fell 73% to $0.81 due to a significant write-off from the Five Prime Therapeutics acquisition, while non-GAAP EPS rose 4% to $4.38. Operating income on a GAAP basis dropped 64% to $0.8 billion, leading to a 25.8 percentage point decrease in operating margin to 13.5%. Free cash flow was $1.7 billion, down from $2.7 billion in Q2 2020. Amgen reaffirmed its total revenue guidance for 2021 at $25.8 to $26.6 billion, while revising GAAP EPS guidance downwards.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.46%
Tags
-
Rhea-AI Summary

Amgen (NASDAQ: AMGN) has declared a $1.76 per share dividend for Q3 2021, set to be paid on September 8, 2021, to stockholders of record by August 17, 2021. This action reflects the company's ongoing commitment to returning value to its shareholders. Amgen continues to focus on developing innovative therapeutics to address unmet medical needs and improve patient health outcomes. The company, established in 1980, is recognized as a leader in biotechnology, striving to advance its pipeline of medicines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
dividends
Rhea-AI Summary

Amgen announced the appointment of S. Omar Ishrak to its Board of Directors, effective immediately. Dr. Ishrak, a seasoned leader with extensive experience in the healthcare sector, will also serve on the Corporate Responsibility and Compliance Committee and the Compensation and Management Development Committee. With this addition, Amgen's Board now comprises 12 directors, 11 of whom are independent. Ishrak previously served as CEO of Medtronic and has held pivotal roles at GE Healthcare. His expertise is expected to enhance Amgen's focus on innovation and patient care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
management
-
Rhea-AI Summary

Amgen (NASDAQ:AMGN) will report its Q2 2021 financial results on August 3, 2021, after U.S. market close. A conference call is scheduled for 2:00 p.m. PT, featuring CEO Robert A. Bradway and senior management. The call will be broadcast live and accessible to the media and general public. Amgen, a leader in biotechnology since 1980, focuses on developing therapies for serious illnesses through advanced human genetics, with a commitment to improving health outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
-
Rhea-AI Summary

Amgen has announced an agreement to acquire Teneobio for $900 million in upfront cash, with potential future milestone payments of up to $1.6 billion. Teneobio specializes in Human Heavy-Chain Antibodies and its advanced bispecific and multispecific antibody technologies will enhance Amgen's capabilities in treating various diseases. The acquisition adds TNB-585, a Phase 1 bispecific T-cell engager for metastatic prostate cancer, along with several preclinical oncology assets. The deal is expected to close in the second half of 2021, pending regulatory approvals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
Rhea-AI Summary

Amgen (NASDAQ:AMGN) has partnered with the International Federation of Psoriasis Associations to launch the UPLIFT Innovation Challenge, aimed at improving health outcomes for individuals with psoriatic disease. Applicants can submit innovative ideas by August 30, 2021, for a chance to receive a grant of $25,000 USD. This initiative responds to findings from the 2020 UPLIFT survey, which highlighted significant gaps in treatment and patient-provider communication. Notably, it found only 50% of those with psoriatic arthritis saw a healthcare provider within the past year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
none
-
Rhea-AI Summary

Amgen (NASDAQ:AMGN) announced that the FDA has accepted its Biologics License Application for tezepelumab, granting it Priority Review for asthma treatment. This decision was based on the PATHFINDER clinical trial results, particularly the NAVIGATOR Phase 3 trial, where tezepelumab showed superiority over placebo for patients with uncontrolled asthma. The FDA aims to make a decision by Q1 2022. This innovative treatment addresses a significant unmet medical need, as many patients do not respond well to current therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
none
-
Rhea-AI Summary

Amgen (NASDAQ:AMGN) has received marketing approval from the Japanese Ministry of Health, Labour and Welfare for Aimovig® (erenumab), the first treatment in Japan targeting the calcitonin gene-related peptide receptor for migraine prevention in adults. This marks Amgen K.K.'s first independent submission and approval. Aimovig demonstrated a significant reduction in monthly migraine days in clinical trials. With approximately 8.4 million migraine sufferers in Japan, this approval aims to increase access to effective migraine treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
none
Rhea-AI Summary

deCODE genetics, a subsidiary of Amgen, has developed a blood-based predictor to estimate time to all-cause death, outperforming traditional risk factors. The research analyzed nearly 5,000 protein measurements from 22,913 Icelanders, revealing a significant correlation between protein profiles and mortality. The predictor effectively identifies individuals at both high and low risk of death within a decade. Key findings include the role of growth/differentiation factor 15 (GDF15) in predicting mortality.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
none
Amgen Inc

Nasdaq:AMGN

AMGN Rankings

AMGN Stock Data

148.96B
536.44M
0.22%
82.06%
3.01%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States
THOUSAND OAKS